The IP3R receptor ia a cell receptor broadly involved in intracellular calcium signaling. Researchers have now found that the receptor can be locked into a closed state by enzyme action, and that this locking may potentially play a role in the reduction of neuron signaling seen in neurodegenerative diseases such as Huntington disease and Alzheimer’s disease.
Experiments with both human cells and a mouse model of Huntington’s disease revealed that transglutaminase type 2, a protein cross-linking enzyme elevated in the cells of patients with neurodegenerative diseases, interacts with the IP3R receptor to lock it in a closed non-functional conformation preventing it from fulfilling its essential calcium-releasing role.
Researchers identified a specific amino acid site on the receptor, Gln2746, where the modification takes place. the finding deepens understanding of how receptors are locked and potentially opening the door to studies on other functional proteins that are also regulated by conformational changes.
The channel plays a crucial role in intracellular calcium signaling, and is involved in a wide range of cell functions including mitochondrial energy production and the regulation of autophagy, the process through which cells consume and degrade unused components to maintain a healthy balance of functional proteins.
Although autophagy is normally a mechanism that sustains cell maintenance, it can also trigger a loss of cell function and has been associated with prominent diseases including Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease.
With this work, the scientists propose a general model under which abnormal IP3R-mediated calcium signaling caused by the action of transglutamase type 2 leads to cellular dysfunction and subsequently to the emergence of progressive brain dysfunction.
Transglutaminase 2 activation is commonly associated with inflammation and stress, and its action on the IP3R channel might provide an explanation for the initiation and progression steps common to different neurodegenerative diseases.
According to study leader Katsuhiko Mikoshiba:
“We think that the mechanism we identified in this study could provide us with a more general model of other diseases both of the brain and other parts of the body, where transglutaminase type 2 is upregulated. We hope that this insight could eventually lead to the development of new drug therapies for a number of neurodegenerative diseases that place a high burden on patients and society.”